China institute signs deal on early-stage products
This article was originally published in Scrip
Executive Summary
The government-sponsored Guangzhou Institutes of Biomedicine and Health (GIBH), a branch of the Chinese Academy of Sciences, has signed an agreement with Huya Bioscience International giving it the exclusive right of first review and negotiation for the licensing and development of certain GIBH compounds.